Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations

Journal of Rheumatology

Volumn 35, Issue 10, 2008, Pages 2017-2023

  Seo, Philip ^a   Specks, Ulrich ^b   Keogh, Karina A ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Mayo Clinic   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

Rituximab; Vasculitis; Wegener's granulomatosis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CHLORAMBUCIL; CIDOFOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB;

ADULT; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; CHRONIC SINUSITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE PAIN; FATIGUE; FEMALE; HEMOPTYSIS; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; LUNG BIOPSY; LUNG LESION; LUNG NODULE; MALE; NIGHT SWEAT; NOSE INFLAMMATION; ORBIT PSEUDOTUMOR; PANCREATITIS; PANCYTOPENIA; PRIORITY JOURNAL; RASH; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SINUSITIS; SUBGLOTTIC STENOSIS; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; WEGENER GRANULOMATOSIS; YOUNG ADULT;

EID: 54949130573     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Seo P, Stone JH. The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004;117:39-50.
2. Walton EW, Leggat PO. Wegener's granulomatosis. J Clin Pathol 1956;9:31-7.
3. Carrington CB, Liebow A. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1966;41:497-527.
4. DeRemee RA, McDonald TJ, Harrison EG Jr, Coles DT. Wegener's granulomatosis: anatomic correlates, a proposed classification. Mayo Clinic Proc 1976;51:777-81.
5. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992;35:1322-9.
6. MacFarlane DG, Bourne JT, Dieppe PA, Easty DL. Indolent Wegener's granulomatosis. Ann Rheum Dis 1983;42:398-407.
7. The WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002;23:450-68.
8. Fauci AS, Katz P, Haymes BF, Wolff SM. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. New Engl J Med 1979;301:235-8.
9. Hoffmann GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
10. De Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998;25:492-5.
11. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Arthritis Rheum 2000;43:1836-40.
12. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
13. Golbin JM, Specks U. Part 2: Synopsis of B-lymphocyte targeted therapy of ANCA associated vasculitis. Clin Exp Rheumatol 2007;25:S74-76.
14. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
15. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005;257:540-8.
16. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005;34:229-32.
17. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006;65:853-8.
18. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-7.
19. Gibson LE, Specks U, Homburger H. Clinical utility of ANCA tests for the dermatologist. Int J Dermatol 2003;42:859-69.
20. Ardehali H, Volmar K, Roberts C, Forman M, Becker LC. Fatal disseminated adenoviral infection in a renal transplant patient. Transplantation 2001;71:998-9.
21. Minter RM, Rectenwald JE, Fukuzuka K, et al. TNF-alpha receptor signaling and IL-10 gene therapy regulate the innate and humoral immune responses to recombinant adenovirus in the lung. J Immunol 2000;164:443-51.
22. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: A systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182-9.
23. Freim Wahl SG, Folvik MR, Torp SH. Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: Case report and review of the literature. Clin Neuropathol 2007;26:68-73.
24. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
25. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001;44:2836-40.
26. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8.
27. Katzenstein AL, Locke WK. Solitary lung lesions in Wegener's granulomatosis. Pathologic findings and clinical significance in 25 cases. Am J Surg Pathol 1995;19:545-52.
28. Edwards JCW, Szczepanski L, Szechinshi J, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med 2004;350:2572-81.